HBCLs, not-otherwise specified (NOS), are rare and heterogeneous; other than having germinal center B-cell phenotype, and in up to 45%, a single-hit MYC rearrangement, they have no unifying immunophenotypic or cytogenetic characteristics. This review discusses the current clinicopathologic concept of HGBL, NOS, and looks at potential future taxonomy enrichments based on emerging molecular diagnostics.